AMP-activated protein kinase couples 3-bromopyruvate-induced energy depletion to apoptosis via activation of FoxO3a and upregulation of proapoptotic Bcl-2 proteins

Molecular Carcinogenesis

Volumn 55, Issue 11, 2016, Pages 1584-1597

  Bodur, Cagri ^a   Karakas, Bahriye ^a   Timucin, Ahmet Can ^a   Tezil, Tugsan ^a   Basaga, Huveyda ^a  

^a SABANCI UNIVERSITY   (Turkey)

Author keywords

3 bromopyruvate; AMPK; apoptosis; bcl 2; bim; foxO3a; warburg

Indexed keywords

3 BROMOPYRUVATE; ANTINEOPLASTIC AGENT; BIM PROTEIN; CASPASE 3; CASPASE 9; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; PYRUVIC ACID DERIVATIVE; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR FKHRL1; UNCLASSIFIED DRUG; ADENOSINE TRIPHOSPHATE; BROMOPYRUVATE; FOXO3 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; FLOW CYTOMETRY; GLYCOLYSIS; HCT116 CELL LINE; HELA CELL LINE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LUCIFERASE ASSAY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; TRANSCRIPTION INITIATION; UPREGULATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HCT 116 CELL LINE; METABOLISM; NEOPLASMS; SIGNAL TRANSDUCTION;

ADENOSINE TRIPHOSPHATE; AMP-ACTIVATED PROTEIN KINASES; APOPTOSIS; CELL PROLIFERATION; CELL SURVIVAL; FORKHEAD BOX PROTEIN O3; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOLYSIS; HCT116 CELLS; HELA CELLS; HUMANS; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRUVATES; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION;

EID: 84941687253     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22411     Document Type: Article

References (65)

1. Warburg O. On the origin of cancer cells. Science 1956; 123:309–314.
2. Ko YH, Pedersen PL, Geschwind JF. Glucose catabolism in the rabbit VX2 tumor model for liver cancer: Characterization and targeting hexokinase. Cancer Lett 2001; 173:83–91.
3. Pedersen PL. The cancer cell's “power plants” as promising therapeutic targets: An overview. J Bioenerg Biomembr 2007; 39:1–12.
4. Bonnet S, Archer SL, Allalunis-Turner J. et al. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 2007; 11:37–51.
5. Robinson GL, Dinsdale D, Macfarlane M, Cain K. Switching from aerobic glycolysis to oxidative phosphorylation modulates the sensitivity of mantle cell lymphoma cells to TRAIL. Oncogene 2012; 31:4996–5006.
6. Strum SB, Adalsteinsson O, Black RR, Segal D, Peress NL, Waldenfels J. Case report: Sodium dichloroacetate (DCA) inhibition of the “Warburg Effect“ in a human cancer patient: Complete response in non-Hodgkin's lymphoma after disease progression with rituximab-CHOP. J Bioenerg Biomembr 2013; 45:307–315.
7. Chen Z, Zhang H, Lu W, Huang P. Role of mitochondria-associated hexokinase II in cancer cell death induced by 3-bromopyruvate. Biochim Biophys Acta 2009; 1787:553–560.
8. Ganapathy-Kanniappan S, Geschwind JF, Kunjithapatham R. et al. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is pyruvylated during 3-bromopyruvate mediated cancer cell death. Anticancer Res 2009; 29:4909–4918.
9. Kim JS, Ahn KJ, Kim JA. et al. Role of reactive oxygen species-mediated mitochondrial dysregulation in 3-bromopyruvate induced cell death in hepatoma cells: ROS-mediated cell death by 3-BrPA. J Bioenerg Biomembr 2008; 40:607–618.
10. Geschwind JF, Ko YH, Torbenson MS, Magee C, Pedersen PL. Novel therapy for liver cancer: Direct intraarterial injection of a potent inhibitor of ATP production. Cancer Res 2002; 62:3909–3913.
11. Ko YH, Smith BL, Wang Y. et al. Advanced cancers: Eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun 2004; 324:269–275.
12. Schaefer NG, Geschwind JF, Engles J, Buchanan JW, Wahl RL. Systemic administration of 3-bromopyruvate in treating disseminated aggressive lymphoma. Transl Res 2012; 159:51–57.
13. Calvino E, Estan MC, Sanchez-Martin C. et al. Regulation of death induction and chemosensitizing action of 3-bromopyruvate in myeloid leukemia cells: Energy depletion, oxidative stress, and protein kinase activity modulation. J Pharmacol Exp Ther 2014; 348:324–335.
14. Ota S, Geschwind JF, Buijs M, Wijlemans JW, Kwak BK, Ganapathy-Kanniappan S. Ultrasound-guided direct delivery of 3-bromopyruvate blocks tumor progression in an orthotopic mouse model of human pancreatic cancer. Target Oncol 2013; 8:145–151.
15. Isayev O, Rausch V, Bauer N. et al. Inhibition of glucose turnover by 3-bromopyruvate counteracts pancreatic cancer stem cell features and sensitizes cells to gemcitabine. Oncotarget 2014; 5:5177–5189.
16. Sanchez-Arago M, Cuezva JM. The bioenergetic signature of isogenic colon cancer cells predicts the cell death response to treatment with 3-bromopyruvate, iodoacetate or 5-fluorouracil. J Transl Med 2011; 9:19.
17. El Sayed SM, Abou El-Magd RM, Shishido Y. et al. D-amino acid oxidase gene therapy sensitizes glioma cells to the antiglycolytic effect of 3-bromopyruvate. Cancer Gene Ther 2012; 19:1–18.
18. Kutuk O, Basaga H. Bcl-2 protein family: Implications in vascular apoptosis and atherosclerosis. Apoptosis 2006; 11:1661–1675.
19. Muscarella DE, Bloom SE. The contribution of c-Jun N-terminal kinase activation and subsequent Bcl-2 phosphorylation to apoptosis induction in human B-cells is dependent on the mode of action of specific stresses. Toxicol Appl Pharmacol 2008; 228:93–104.
20. Hardie DG. AMPK-Sensing Energy while Talking to Other Signaling Pathways. Cell Metab 2014; 20:939–952.
21. Tong WH, Sourbier C, Kovtunovych G. et al. The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities, and lowers cellular iron levels. Cancer Cell 2011; 20:315–327.
22. Ihlemann J, Ploug T, Hellsten Y, Galbo H. Effect of tension on contraction-induced glucose transport in rat skeletal muscle. Am J Physiol 1999; 277:E208–E214.
23. Bultot L, Guigas B, Von Wilamowitz-Moellendorff A. et al. AMP-activated protein kinase phosphorylates and inactivates liver glycogen synthase. Biochem J 2012; 443:193–203.
24. Davies SP, Sim AT, Hardie DG. Location and function of three sites phosphorylated on rat acetyl-CoA carboxylase by the AMP-activated protein kinase. Eur J Biochem 1990; 187:183–190.
25. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003; 115:577–590.
26. Meisse D, Van de Casteele M, Beauloye C. et al. Sustained activation of AMP-activated protein kinase induces c-Jun N-terminal kinase activation and apoptosis in liver cells. FEBS Lett 2002; 526:38–42.
27. Kefas BA, Cai Y, Ling Z. et al. AMP-activated protein kinase can induce apoptosis of insulin-producing MIN6 cells through stimulation of c-Jun-N-terminal kinase. J Mol Endocrinol 2003; 30:151–161.
28. Zhang WB, Wang Z, Shu F. et al. Activation of AMP-activated protein kinase by temozolomide contributes to apoptosis in glioblastoma cells via p53 activation and mTORC1 inhibition. J Biol Chem 2010; 285:40461–40471.
29. Chiacchiera F, Matrone A, Ferrari E. et al. P38alpha blockade inhibits colorectal cancer growth in vivo by inducing a switch from HIF1alpha- to FoxO-dependent transcription. Cell Death Differ 2009; 16:1203–1214.
30. Chang HW, Lee YS, Nam HY. et al. Knockdown of beta-catenin controls both apoptotic and autophagic cell death through LKB1/AMPK signaling in head and neck squamous cell carcinoma cell lines. Cell Signal 2013; 25:839–847.
31. Dhanasekaran DN, Reddy EP. JNK signaling in apoptosis. Oncogene 2008; 27:6245–6251.
32. Filomeni G, Cardaci S, Da Costa Ferreira AM, Rotilio G, Ciriolo MR. Metabolic oxidative stress elicited by the copper(II) complex [Cu(isaepy) 2] triggers apoptosis in SH-SY5Y cells through the induction of the AMP-activated protein kinase/p38MAPK/p53 signalling axis: Evidence for a combined use with 3-bromopyruvate in neuroblastoma treatment. Biochem J 2011; 437:443–453.
33. Greer EL, Oskoui PR, Banko MR. et al. The energy sensor AMP-activated protein kinase directly regulates the mammalian FOXO3 transcription factor. J Biol Chem 2007; 282:30107–30119.
34. Bunz F, Dutriaux A, Lengauer C. et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998; 282:1497–1501.
35. Zhang L, Yu J, Park BH, Kinzler KW, Vogelstein B. Role of BAX in the apoptotic response to anticancer agents. Science 2000; 290:989–992.
36. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29:e45.
37. Kim KY, Baek A, Hwang JE. et al. Adiponectin-activated AMPK stimulates dephosphorylation of AKT through protein phosphatase 2A activation. Cancer Res 2009; 69:4018–4026.
38. Leclerc GM, Leclerc GJ, Fu G, Barredo JC. AMPK-induced activation of Akt by AICAR is mediated by IGF-1R dependent and independent mechanisms in acute lymphoblastic leukemia. J Mol Signal 2010; 5:15.
39. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307:1098–1101.
40. Gilley J, Coffer PJ, Ham J. FOXO transcription factors directly activate bim gene expression and promote apoptosis in sympathetic neurons. J Cell Biol 2003; 162:613–622.
41. You H, Pellegrini M, Tsuchihara K. et al. FOXO3a-dependent regulation of Puma in response to cytokine/growth factor withdrawal. J Exp Med 2006; 203:1657–1663.
42. Glauser DA, Schlegel W. The emerging role of FOXO transcription factors in pancreatic beta cells. J Endocrinol 2007; 19:195–207.
43. Yu T, Ji J, Guo YL. MST1 activation by curcumin mediates JNK activation, Foxo3a nuclear translocation and apoptosis in melanoma cells. Biochem Biophys Res Commun 2013; 441:53–58.
44. Kopycinska J, Kempinska-Podhorodecka A, Haas T. et al. Activation of FoxO3a/Bim axis in patients with Primary Biliary Cirrhosis. Liver Int 2013; 33:231–238.
45. Sunters A, Fernandez de Mattos S, Stahl M. et al. FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines. J Biol Chem 2003; 278:49795–49805.
46. Whitfield J, Neame SJ, Paquet L, Bernard O, Ham J. Dominant-negative c-Jun promotes neuronal survival by reducing BIM expression and inhibiting mitochondrial cytochrome c release. Neuron 2001; 29:629–643.
47. Wong HK, Fricker M, Wyttenbach A. et al. Mutually exclusive subsets of BH3-only proteins are activated by the p53 and c-Jun N-terminal kinase/c-Jun signaling pathways during cortical neuron apoptosis induced by arsenite. Mol Cell Biol 2005; 25:8732–8747.
48. Gwak GY, Yoon JH, Kim KM, Lee HS, Chung JW, Gores GJ. Hypoxia stimulates proliferation of human hepatoma cells through the induction of hexokinase II expression. J Hepatol 2005; 42:358–364.
49. Zhang Q, Pan J, North PE. et al. Aerosolized 3-bromopyruvate inhibits lung tumorigenesis without causing liver toxicity. Cancer Prev Res (Phila) 2012; 5:717–725.
50. Xiao H, Li S, Zhang D, Liu T, Yu M, Wang F. Separate and concurrent use of 2-deoxy-D-glucose and 3-bromopyruvate in pancreatic cancer cells. Oncol Rep 2013; 29:329–334.
51. Yu SJ, Yoon JH, Lee JH. et al. Inhibition of hypoxia-inducible carbonic anhydrase-IX enhances hexokinase II inhibitor-induced hepatocellular carcinoma cell apoptosis. Acta Pharmacol Sin 2011; 32:912–920.
52. Hawley SA, Boudeau J, Reid JL. et al. Complexes between the LKB1 tumor suppressor, STRAD alpha/beta, and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J Biol 2003; 2:28.
53. Ben Sahra I, Tanti JF, Bost F. The combination of metformin and 2-deoxyglucose inhibits autophagy and induces AMPK-dependent apoptosis in prostate cancer cells. Autophagy 2010; 6:670–671.
54. Levesley J, Steele L, Taylor C, Sinha P, Lawler SE. ABT-263 enhances sensitivity to metformin and 2-deoxyglucose in pediatric glioma by promoting apoptotic cell death. PLoS ONE 2013; 8:e64051.
55. Brunet A, Bonni A, Zigmond MJ. et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999; 96:857–868.
56. Brunet A, Park J, Tran H, Hu LS, Hemmings BA, Greenberg ME. Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a). Mol Cell Biol 2001; 21:952–965.
57. Hu MC, Lee DF, Xia W. et al. IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 2004; 117:225–237.
58. Ho KK, McGuire VA, Koo CY. et al. Phosphorylation of FOXO3a on Ser-7 by p38 promotes its nuclear localization in response to doxorubicin. J Biol Chem 2012; 287:1545–1555.
59. Sunayama J, Tsuruta F, Masuyama N, Gotoh Y. JNK antagonizes Akt-mediated survival signals by phosphorylating 14-33. J Cell Biol 2005; 170:295–304.
60. Chen L, Willis SN, Wei A. et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005; 17:393–403.
61. Kim H, Rafiuddin-Shah M, Tu HC. et al. Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat Cell Biol 2006; 8:1348–1358.
62. Ameyar M, Wisniewska M, Weitzman JB. A role for AP-1 in apoptosis: The case for and against. Biochimie 2003; 85:747–752.
63. Bodur C, Kutuk O, Karsli-Uzunbas G, Isimjan TT, Harrison P, Basaga H. Pramanicin analog induces apoptosis in human colon cancer cells: Critical roles for Bcl-2, Bim, and p38 MAPK signaling. PLoS ONE 2013; 8:e56369.
64. Meynet O, Zunino B, Happo L. et al. Caloric restriction modulates Mcl-1 expression and sensitizes lymphomas to BH3 mimetic in mice. Blood 2013; 122:2402–2411.
65. Ramirez-Peinado S, Alcazar-Limones F, Lagares-Tena L. et al. 2-deoxyglucose induces Noxa-dependent apoptosis in alveolar rhabdomyosarcoma. Cancer Res 2011; 71:6796–6806.